What we do Vaishali Pharma Ltd specializes in pharmaceutical formulations, active pharmaceutical ingredients, surgical products, veterinary supplements, and nutraceuticals for domestic and export markets. |
Founded in 2,008 |
Market share Vaishali Pharma is a recognized 'One Star Export House' with over 250 formulation brands and an expanding global footprint. |
Problem solved The company addresses global health needs by supplying quality pharmaceuticals, surgical, and veterinary products certified by international standards. |
Top clients or who we serve Serving pharmaceutical companies, healthcare providers, veterinary sectors, and nutraceutical markets globally in B2B and export domains. |
Key management Atul Vasani (Chairman & Managing Director), Jagruti Vasani (Whole-time Director), Dewansh Ajay Vasani (Executive Director & CFO), Hemant Pathak (CEO). |
Our journey and innovations Founded in 2008, IPO in 2017, expanded into formulation manufacturing, surgical products and export verticals with ISO and international certifications. |
Where we operate Domestic Indian markets and export markets across multiple countries worldwide with dossiers in CTD format supporting exports. |
Top products or what we offer Pharmaceutical formulations, APIs, surgical instruments, veterinary supplements, herbal and nutraceutical products. |
Top brands 250+ formulation brands with bioequivalence dossiers, surgical division certified by European and WHO GMP standards. |
Raw materials needed Active pharmaceutical ingredients and raw materials for formulations and surgical instruments sourced from certified suppliers. |
Raw materials supplier Sourced globally from WHO-GMP and ISO certified manufacturers and suppliers specialized in pharmaceuticals and surgical products. |
Recurring vs cyclical contribution Revenue primarily from cyclical pharmaceutical sales with recurring orders in both domestic and export businesses. |
Our industry position Renowned exporter with strong compliance, growing domestic trading presence in APIs, and emerging formulation export footprint. |
Financial highlights FY2024-25 revenue approx. Rs. 102 crore with net profit at Rs. 0.82 crore, showing steady growth over previous years. |
Geographical revenue split 67.97% revenue from domestic operations; 29.91% from exports in FY2024-25. |
Order book - |
Whats driving growth Expansion in export markets, enhanced product portfolio, strategic collaborations, and compliance with global certifications. |
Our future plans Scaling formulation exports, new product launches, enhancing manufacturing capabilities, and strategic investments in pharma sector. |
Our green promise - |
Our people and values Focus on ethical practices, corporate governance, inclusive work culture, and compliance with workplace safety and maternity benefits. |
Key challenges ahead Regulatory changes, competition, managing forex fluctuations, and maintaining certification standards internationally. |
Interesting facts Recognized as 'One Star Export House'; offers over 250 dossiers in CTD format; strong ISO and EU certifications. |
Risks and strategy Mitigates risks via internal financial controls, regular audits, regulatory compliance, and diversified product presence. |
